stockrow
Monday 9 November 2026
Export IXHL’s income statement to Excel — free account
Incannex Healthcare Inc.
IXHLHealthcare Drug Manufacturers Specialty & Generic
Incannex Healthcare Inc.’s revenue for fiscal 2025 (year ended June 2025) was $86,000.00, up 616.7% from fiscal 2024.
- Revenue
- −92.3%
- EPS
- +98.6%
- Free cash flow
- +327.7%
Quarter to June 2026, against a year earlier
2.24
0.03
−1.32%
Follow IXHL
Alert me
| Jun '17 | Jun '18 | Jun '19 | Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Piotroski F-Score |
— | — | — | — | — | 6 | 5 | 3 | 3 | — |
P/S ratio |
266,845.52 | 266,845.52 | — | 266,845.52 | 266,845.52 | 73,245.27 | 45,498.60 | 24.03 | 4.76 | — |
Altman Z-Score |
— | — | — | — | — | 299.63 | 11.64 | (9.27) | (13.23) | — |
Altman Z″-Score (non-manufacturers) |
— | (181.82) | — | (29.79) | (9.20) | 17.24 | (13.64) | (26.91) | (26.78) | — |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
(136,031.98) | (136,031.98) | — | (136,031.98) | (136,031.98) | (15,631.51) | (35,161.88) | (13.08) | (5.01) | — |
Beneish M-Score |
— | — | — | — | — | (1.23) | (10.17) | 3,578.30 | (5.82) | — |
P/B ratio |
37,504.72 | 37,504.72 | — | 37,504.72 | 37,504.72 | 5,581.53 | 4,332.55 | 4.25 | 0.55 | — |
Price to Tangible BV |
37,576.93 | 37,576.93 | — | 37,576.93 | 37,576.93 | 5,581.53 | 0.00 | 4.25 | 0.55 | — |
EV/Sales |
266,838.29 | 266,838.29 | — | 266,838.29 | 266,838.29 | 73,231.55 | 45,487.72 | 21.34 | (2.45) | — |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | — |
EV/Operating CF |
(49,150.21) | (49,150.21) | — | (49,150.21) | (49,150.21) | (7,880.69) | (4,504.56) | (2.67) | 0.31 | — |
EV/FCF |
(49,150.21) | (49,150.21) | — | (49,150.21) | (49,150.21) | (7,880.69) | (4,433.49) | (2.62) | 0.31 | — |
Quick Ratio |
0.79 | 0.28 | 0.22 | 3.75 | 12.31 | 18.80 | 8.75 | 2.79 | 2.75 | 48.45 |
Current Ratio |
1.09 | 0.49 | 0.41 | 3.95 | 12.36 | 18.84 | 9.02 | 2.88 | 2.86 | 48.81 |
Net Debt/EBITDA |
0.04 | (0.03) | 0.02 | 0.90 | 0.80 | 2.52 | 0.45 | 0.20 | 0.64 | 2.97 |
Debt/Assets |
0.00% | 49.44% | 12.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(2.35) | (0.91) | (0.16) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.34 | 2.86 | 0.00 | 0.31 | 0.29 | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.13 | 0.97 | 0.79 | 0.83 | 0.61 | 0.86 | 0.22 | 0.86 | 0.27 | 0.67 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | — | — | (3.59) | (2.69) | (0.03) | (0.04) |
Interest Coverage |
(101.51) | (325.05) | 0.00 | (1,788.13) | (6,076.89) | (2,488.66) | (206.72) | — | (78.51) | — |
| 7,693.35% | 1,055.51% | 660.44% | (343.08%) | (198.54%) | (66.60%) | (208.38%) | (115.22%) | (381.09%) | (47.80%) | |
| (2,460.51%) | (832.89%) | (428.85%) | (197.18%) | (172.48%) | (62.69%) | (190.43%) | (90.42%) | (250.09%) | (41.32%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (350.36%) | 0.00% | 0.00% |
Return on Tangible Assets |
(18,507.51%) | 648.77% | 582.60% | (148.45%) | (132.65%) | (41.55%) | (235.34%) | (166.99%) | (355.05%) | (27.06%) |
Average Days of Receivables |
120.63 | 19.51 | 0.00 | 207.22 | 31.93 | 136.38 | 76.21 | 299,208.75 | 17,536.98 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | 245.68% | 681.11% | 4,494.61% | 107,325.00% | 12,496.51% | 0.00% |
Selling, General and Administrative Expense of Revenue |
769.01% | 239.71% | 0.00% | 518.85% | 299.40% | 825.15% | 864.48% | 143,116.67% | 15,265.12% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | 0.00% | 185.69% | 231.87% | 74,400.00% | 3,033.72% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 1.74 | — |
Graham Number |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% | (3.08%) | (38.87%) | (557.26%) | — |
Free Cash Flow Yield |
0.00% | 0.00% | — | 0.00% | 0.00% | (0.01%) | (0.02%) | (33.84%) | (168.62%) | — |
Revenue per Share |
0.03 | 0.06 | 0.00 | 0.00 | 0.01 | 0.36 | 1.81 | 0.02 | 0.07 | 0.00 |
Operating CF per Share |
(0.27) | (0.16) | (0.01) | (0.02) | (0.02) | (5.86) | (20.98) | (29.44) | (10.90) | (1.10) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.62) | (0.51) | (0.01) | 0.00 |
Free Cash Flow per Share |
(0.27) | (0.16) | (0.01) | (0.02) | (0.02) | (5.86) | (21.60) | (29.95) | (10.91) | (1.10) |
Cash per Share |
0.05 | 0.01 | 0.00 | 0.01 | 0.03 | 17.15 | 43.18 | 10.88 | 13.10 | 5.81 |
Shareholders Equity per Share |
(0.02) | (0.02) | 0.00 | 0.01 | 0.03 | 16.40 | 40.65 | 20.84 | 11.66 | 5.78 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.02) | (0.02) | 0.00 | 0.01 | 0.03 | 16.40 | 40.65 | 20.84 | 11.66 | 5.78 |
Free Cash Flow |
(2.07) | (2.11) | (1.51) | (2.68) | (5.20) | (9.29) | (11.06) | (16.12) | (12.52) | (12.88) |
Working Capital |
0.05 | (0.41) | (0.39) | 2.17 | 6.45 | 26.02 | 20.45 | 10.58 | 12.98 | 71.34 |
Capital Expenditures |
(0.04) | (0.04) | (0.02) | — | — | — | (0.32) | (0.28) | (0.01) | (0.01) |
Net Current Asset Value |
(0.25) | (0.41) | (0.39) | 2.17 | 6.45 | 26.02 | 20.04 | 10.37 | 12.90 | 67.22 |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | — |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.34 | 23.08 | 0.09 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.70 | 0.56 | 0.49 | 0.00 | — | — | 0.30 | 0.22 | 1.08 | 60.00 |
Cash ROIC |
(359.05%) | (1,276.76%) | 834.45% | (57.73%) | (39.04%) | (17.46%) | (25.77%) | (94.42%) | (44.04%) | (9.53%) |
Accounts Receivable Turnover |
3.88 | 13.42 | 0.00 | 2.74 | 7.09 | 3.36 | 4.55 | 0.00 | 0.01 | 0.00 |
Accounts Payable Turnover |
2.31 | 3.59 | 0.09 | 2.00 | 7.29 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
5.06 | 7.86 | 0.22 | 5.74 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
160.30 | 100.15 | 3,276.29 | 221.11 | 30.29 | 115,736.74 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
74.10 | 45.14 | 1,331.07 | 68.65 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.06 | 0.06 | 0.06 | 0.18 | 0.21 | 0.17 | 0.20 | 5.02 | 6.98 | 4.36 |
Average Payables |
0.37 | 0.37 | 0.31 | 0.33 | 0.29 | 0.82 | 1.60 | 1.18 | 3.36 | 3.63 |
Average Inventory |
0.17 | 0.17 | 0.14 | 0.12 | — | — | — | — | — | — |
Average Assets |
0.65 | 0.26 | 0.44 | 1.63 | 4.96 | 17.25 | 25.63 | 20.42 | 18.75 | 46.71 |
Average Common Equity |
(0.21) | (0.21) | (0.29) | 0.94 | 4.31 | 16.23 | 23.42 | 16.02 | 12.30 | 40.38 |
Columns are period end dates · fundamentals updated 26 Oct 2026